Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 2 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 47
States / cities: Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Hypertension, Glaucoma, Open-Angle
Interventions: Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Morrow, Georgia • High Point, North Carolina • Mt. Pleasant, South Carolina

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Primary Open Angle Glaucoma
Interventions: XEN63 Glaucoma Treatment System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Culver City, California • Petaluma, California + 25 more

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: T-2345, Xalatan; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Glaucoma Open-angle
Interventions: Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions: Direct Selective Laser Trabeculoplasty (DSLT); Device
Lead sponsor: Ngoc Nguyen Inc.; Other
Eligibility: 20 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Jose, California

Conditions: Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions: miLens system; Device
Lead sponsor: Smartlens, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Fullerton, California • Petaluma, California • Torrance, California

Conditions: Glaucoma, Primary Open Angle
Interventions: oxygen inhalation, Adaptive optics imaging; Other · Device
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Primary Open Angle Glaucoma
Interventions: Caffeinated Coffee, Decaffeinated Coffee; Other
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 89 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Ocular Hypertension
Interventions: INO-8875, Placebo; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions: Travaprost without BAC (Travatan Z); Drug
Lead sponsor: United States Air Force; Federal
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System (L-PPDS); Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Glaucoma
Interventions: Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Newport Beach, California • Largo, Florida • Miami, Florida + 7 more

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: AqueSys XEN 45 Glaucoma Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-12286 0.5% Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions: CRADLE, Red reflex testing; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 7 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions: Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant; Drug · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Glaucoma, Open-Angle
Interventions: Methazolamide 25 MG, Methazolamide 50 MG; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Evaluation of Safety and Efficacy of PDP-716

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Excimer Laser Trabeculostomy Glaucoma Treatment Study

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

Adaptive Optics Retinal Imaging

The Effects of Caffeinated Coffee on Intraocular Pressure

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

24-hour Efficacy of AR-12286

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

Ahmed Glaucoma Valve Surgery With Mitomycin-C

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Use of Methazolamide to Lower Intraocular Pressure